Fulgent Genetics, Inc. (FLGT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$21.68

From 52W high−29.69%

Volume669174.00

Market cap$596.81M

P/E (TTM)—

P/S (TTM)1.8x

Div yield—

Key dataSep 18, 2026

Open

$21.68

From 52W high

−29.69%

Volume

669174.00

Market cap

$596.81M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.3x

P/E (TTM)

—

RSI (14)

68.2

MomentumView details →

1D Return

−0.73%

YTD Return

−17.27%

SummaryUpdated Jun 1, 2026

Fulgent Genetics, Inc. (NASDAQ:FLGT) is a California-based medical diagnostics and genetic testing company founded in 2011 and headquartered in Temple City, California. The company went public in September 2016 and has evolved from a COVID-19 testing provider during the pandemic to a comprehensive genetic testing and precision medicine company. Today, Fulgent operates three main business segments: precision diagnostics, anatomic pathology, and biopharma services, while also developing therapeutic drugs through its Fulgent Pharma division.

Ask drillr about Fulgent Genetics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.3x

EV/Sales

1.1x

P/S (TTM)

1.8x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

35.58%

Net Margin

−26.05%

EBITDA Margin

−20.07%

ROE (TTM)

−8.42%

ROA (TTM)

−7.75%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

+6.83%

EPS YoY

−70.91%

FCF YoY

−73.12%

Revenue CAGR 3Y

−19.52%

EPS CAGR 3Y

−39.72%

EBITDA YoY

−48.52%

MomentumView details →

1D Return

−0.73%

YTD Return

−17.27%

1Y Return

−2.63%

RSI (14)

68.2

vs 50D SMA

+10.26%

vs 200D SMA

+7.03%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.34x

Quick Ratio

6.18x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

−26.09%

Beats (12Q)

9/12

Next Q EPS Est

−$0.65

Avg Surprise (4Q)

64.82%

Rev Surprise

−9.16%

Financials snapshotView financials →

Revenue (TTM)

323.93M

Net Income (TTM)

−84.38M

Op. CF (TTM)

−83.70M

Next earningsNov 6, 2026 →

Latest newsMore news →

Fulgent Genetics, Inc. reported a quarterly loss of $0.58 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.46 per share, compared to earnings of $0.07 per share a year ago.52d ago

Similar companies

China Biotech Services Holdings Limited08037.HK Aclaris Therapeutics, Inc.ACRS Prenetics Global LimitedPRE Myriad Genetics, Inc.MYGN Castle Biosciences, Inc.CSTL Biodesix, Inc.BDSX Find similar companies →

Latest newsMore news →